Subcutaneous implantable cardioverter defibrillator in cardiomyopathies and channelopathies

Area of Science:

• Cardiology
• Electrophysiology
• Medical Devices

Background:

• Cardiomyopathies and channelopathies are genetic heart conditions increasing sudden cardiac death (SCD) risk.
• Conventional transvenous implantable cardioverter-defibrillators (ICDs) prevent SCD but carry risks like infection and lead failure.
• Current risk stratification for ICD implantation has low positive predictive value, leading to many patients receiving unnecessary devices.

Purpose of the Study:

• To review the evidence and future outlook of subcutaneous implantable cardioverter-defibrillator (S-ICD) therapy.
• To evaluate S-ICD as an alternative for patients with cardiomyopathies and channelopathies at risk of SCD.

Main Methods:

• Review of existing scientific literature and clinical studies on S-ICD therapy.
• Analysis of S-ICD benefits and limitations in managing arrhythmias in specific patient populations.
• Discussion of S-ICD's advantages over transvenous ICDs, particularly for young patients.

Main Results:

• S-ICD provides effective SCD protection for patients with cardiomyopathies and channelopathies.
• S-ICD eliminates risks associated with intravascular leads, such as infection and lead failure.
• S-ICD is a viable alternative to transvenous ICDs, especially for younger individuals with long-term prognoses.

Conclusions:

• S-ICD offers a significant advancement in SCD prevention for patients with cardiomyopathies and channelopathies.
• The absence of transvenous leads makes S-ICD particularly advantageous for long-term use and in younger patients.
• Future research should focus on optimizing S-ICD use and addressing its limitations, such as the lack of pacing functions.